Synopsis: A pharma stock is trying to move from a small API and intermediates manufacturer into a larger integrated pharma platform. With capacity expansion, acquisitions, regulated market filings, CDMO plans and a new formulations push, the story looks exciting, but what are the risks involved?
A micro-pharma stock trading at Rs. 13.80 has come into focus after the company outlined an aggressive growth plan involving around 30 percent revenue CAGR over the next three years, a major capacity scale-up and expansion across the pharma value chain. The stock currently has a market capitalisation of around Rs. 736.15 crore. Promoter holding stood at 52.68 percent as of March 2026, while FIIs increased their stake from 0.23 percent to 0.32 percent between December and March. DIIs also raised their holding from 2.83 percent in September 2025 to 4.60 percent in March 2026.
Anlon Healthcare Ltd is a Rajkot-based research-driven chemical manufacturer engaged in high-purity pharmaceutical intermediates and active pharmaceutical ingredients, also called APIs. In simple terms, the company does not mainly make final medicines for consumers. It makes the key chemical ingredients that other pharma companies use to make tablets, capsules, syrups and other finished formulations. Its core products are linked to pain and inflammation treatment, including Loxoprofen Sodium Dihydrate, Ketoprofen and Dexketoprofen Trometamol. The company says it is among the few Indian manufacturers of these APIs.
What Does The Company Actually Make?
To understand Anlon, one must first understand APIs and intermediates in simple language. An API is the main active ingredient inside a medicine. If a tablet works to reduce pain, fever or inflammation, the API is the key substance doing that job. A pharmaceutical intermediate is one step before the API. It is a chemical building block used to make the final API.
Anlon’s main APIs are Loxoprofen Sodium Dihydrate, Ketoprofen and Dexketoprofen Trometamol. These are NSAIDs, which means pain-relief and anti-inflammatory ingredients. They are used for pain, inflammation, lower back pain, osteoarthritis, rheumatoid arthritis and fever-related applications. Ketoprofen also has use in veterinary medicine.
The company also makes intermediates such as Ketonitrile, 3-(1-cyanoethyl)benzoic acid, Loxoprofen Acid and Guaiacol Glycidyl Ether. In simple terms, these are not final medicines but important chemicals used to produce APIs. L-Carnitine Tartrate is more of a nutraceutical product, used as a supplement-related ingredient.
Why Is Capacity Expansion So Important?
The biggest trigger in Anlon’s story is capacity. The company had 400 MTPA installed capacity at its Rajkot facility, and in Q3FY26, 84.41 percent capacity was utilised. Management later said in the Q3 earnings call that the existing facility was almost above 90 percent utilised and practically full. The practical message was simple: the company was running close to its limit.
In the Q2FY26 concall, management said the existing 400 MTPA facility could generate around Rs. 170 crore to Rs. 180 crore revenue at peak, with only limited additional upside. It originally planned a 700 MTPA greenfield expansion, which would take total capacity to around 1,100 MTPA. Management said that at 80 to 85 percent utilisation, this expanded capacity could support peak revenue of around Rs. 360 crore to Rs. 400 crore.
However, the story did not stop there. In Q3FY26, Anlon announced acquisitions to add faster capacity. Apiqo Organics added 700 to 800 MTPA capacity, while Bizotic Lifescience was expected to add another 300 to 400 MTPA. Along with Anlon’s existing 400 MTPA capacity, the total projected capacity was expected to reach 1,400 to 1,600 MTPA by FY26. This means capacity could rise by nearly 250 to 300 percent from the original 400 MTPA base.
The logic behind this expansion is clear. Management said the existing plant had become a bottleneck and that if the company could not supply customers, they could start looking for other suppliers. This is why Anlon is using both organic and inorganic expansion rather than waiting only for greenfield capacity.
Acquisitions Are Changing The Business
Apiqo Organics was acquired with a 67.48 percent stake for Rs. 5.40 crore in cash. The company said Apiqo strengthens backward integration for pharmaceutical intermediates, industrial chemicals and fine chemicals. Backward integration simply means Anlon can make more of its own raw materials instead of depending on outside suppliers. This can improve cost control, supply security and operational flexibility.
The Bizotic Lifescience acquisition involved a 56.67 percent stake for Rs. 3.79 crore in cash, with completion expected within Q4FY26. The company said Bizotic provides a ready-to-operate manufacturing facility, reduces greenfield execution risk, strengthens regulatory readiness and improves service capability in domestic API markets.
Management also said Apiqo was already operational and almost 80 to 85 percent utilised, while Bizotic had utilisation of around 50 to 55 percent. For FY27, management indicated that Anlon’s existing plant could contribute around Rs. 170 crore to Rs. 180 crore, Apiqo could contribute around Rs. 125 crore to Rs. 130 crore, and Bizotic could contribute around Rs. 75 crore to Rs. 80 crore after completion.
The latest acquisition takes the story further. In April 2026, Anlon approved the acquisition of 63.98 percent stake in Remember India Health Links Pvt Ltd for Rs. 5.38 crore in cash. This target company is engaged in manufacturing finished pharmaceutical products and formulations such as tablets and capsules. The objective is to transform Anlon from an API manufacturer into a complete pharmaceutical provider by moving beyond APIs into finished dosage formulations and gaining access to more than 30 finished formulation dossiers.
This is important because Anlon is no longer only talking about APIs and intermediates. It is now trying to move further up the pharma value chain, from ingredients to finished medicines, and eventually into domestic and international retail and hospital markets. However, the target company’s FY25 turnover was only Rs. 83.08 lakh, so this is more of a strategic platform acquisition than an immediate revenue booster.
Growth, Margins And Regulatory Push
Anlon’s financial performance has already shown a sharp scale-up. In Q2FY26, total income stood at Rs. 52.32 crore, compared with Rs. 24.21 crore in Q2FY25. EBITDA rose to Rs. 13.77 crore from Rs. 7.57 crore, while PAT increased to Rs. 9.32 crore from Rs. 2.59 crore. For H1FY26, total income rose to Rs. 85.53 crore from Rs. 62.11 crore, while PAT doubled to Rs. 12.86 crore from Rs. 6.36 crore.
In Q3FY26, the company reported total income of Rs. 35.78 crore, compared with Rs. 9.38 crore in Q3FY25. EBITDA stood at Rs. 12.54 crore with margins of 35.06 percent, while PAT came in at Rs. 5.15 crore compared with a loss in the year-ago period. For 9MFY26, total income increased to Rs. 121.32 crore from Rs. 71.49 crore, EBITDA rose to Rs. 32.56 crore and PAT stood at Rs. 18.02 crore.
Management has guided for around 30 percent revenue CAGR over the next three years. It also said the FY27 revenue guidance of Rs. 370 crore to Rs. 380 crore was conservative. On margins, management said Anlon’s existing product portfolio can sustain around 35 percent EBITDA margin, while regulated market products can target around 50 percent EBITDA margin. After adding Apiqo, consolidated margins may be around 30 to 33 percent because Apiqo’s margins are slightly lower.
Regulatory filings are another important part of the story. Anlon has filed 21 DMFs across global markets. It has CEP approval from EDQM Europe for Ketoprofen, ANVISA Brazil approval for Loxoprofen Sodium Dihydrate and NMPA China approval for Loxoprofen Sodium Dihydrate. The company is also progressing DMF submissions for Ketoprofen in the USA and Dexketoprofen Trometamol in key European markets, with approval expected over a couple of years.
CDMO, New APIs And Revenue Mix Shift
Another important growth driver is CDMO. This means Anlon develops and manufactures molecules for other pharma companies. The company said it is developing three molecules for two global innovator companies. In Q2FY26, management said commercialisation was scheduled for Q3FY27. In the Q3FY26 earnings call, management said validation quantity for one molecule had already been dispatched, while validation for two more molecules was expected around June-July of the next financial year.
The company is also planning to launch around seven new APIs in FY27 across additional therapeutic categories. This is important because today a large part of the business is still linked to pain and inflammation products. Management said around 30 to 35 percent of revenue comes from Loxoprofen and Ketoprofen and their intermediates. New APIs and CDMO can help diversify the business over time.
The revenue mix has also shifted sharply. In FY24, APIs contributed 77.61 percent of revenue, while pharmaceutical intermediates contributed 14.58 percent. In FY25, APIs fell to 58.13 percent and intermediates rose to 35.70 percent. In 9MFY26, APIs were 25.62 percent, while pharmaceutical intermediates were 71.81 percent. This shows that Anlon is increasingly becoming an intermediates-heavy business in the near term.
Management explained that this shift is not necessarily negative. Earlier, the company was more focused on domestic APIs. As product registrations and approvals came through, overseas customers started ordering more N-1 intermediates linked to APIs. Management also said margins in export N-1 KSMs can be better than domestic APIs.
Future Multibagger?
The bullish argument for Anlon Healthcare is centered around scale, execution and strategic transformation. The company is rapidly moving from being a small niche API and pharmaceutical intermediates player into a broader integrated pharma platform. With existing capacity already nearing full utilisation, management has aggressively acted through greenfield expansion, Apiqo and Bizotic acquisitions, and now entry into finished dosage formulations through Remember India Health Links. If this strategy works as planned, Anlon could significantly expand both its manufacturing scale and value-chain participation over the next few years.
The company also has several strong long-term growth triggers. These include 21 DMF filings, expanding regulated market approvals across Europe, Brazil and China, planned US filings, around seven new API launches in FY27, and CDMO commercialisation for global innovator companies. Management’s 30 percent revenue CAGR target over three years, along with stable EBITDA guidance, suggests that Anlon could evolve into a much larger specialty pharma business if it successfully executes on expansion while maintaining margins and improving working capital.
The bearish view focuses primarily on execution complexity and financial discipline. Anlon is attempting multiple transformations simultaneously, including large-scale capacity expansion, acquisition integration, backward integration, CDMO commercialisation, new API launches and finished formulation expansion. For a relatively small company, this creates substantial operational and managerial pressure.
Working capital remains one of the biggest concerns. Receivable cycles have been elevated, and while management has outlined plans to reduce working capital days and improve cash flow, failure to deliver on these goals could strain the balance sheet. In addition, aggressive expansion can increase integration risk, debt dependence and operational bottlenecks. If customer demand, regulatory approvals, or execution timelines fall short, growth expectations may moderate sharply.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post ₹14 Pharma Stock Targeting 30% CAGR And 300% Capacity Expansion – A Future Multibagger? appeared first on Trade Brains.